Case study shows significant response to 177Lu-PSMA-617 in metastatic prostate cancer, indicating potential for treatment without traditional therapies.
The treatment of metastatic prostate cancer relies on the use of androgen deprivation therapy, which is associated with many side effects, including adverse cardiovascular outcomes. ¹⁷⁷Lu-vipivotide tetraxetan ([¹⁷⁷Lu]Lu-PSMA-617) is used in the treatment of prostate-specific membrane antigen–expressing metastatic castration-resistant prostate adenocarcinoma. We present the case of a patient with prostate cancer with numerous metastatic lesions who declined androgen deprivation therapy, chemotherapy, and local therapy to the prostate gland and instead received first-line systemic [¹⁷⁷Lu]Lu-PSMA-617. He exhibited a significant response in both the primary cancer and its metastatic foci after 2 doses of the treatment.
No takes yet. Share an insight, caveat, or question.
Giri et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: